<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app17.us.archive.org';v.server_ms=411;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-9863?contentType=xml', '20171003011446')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20171003011446/https://www.guideline.gov/summaries/downloadcontent/ngc-9863?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20171003011446/https://www.guideline.gov/summaries/downloadcontent/ngc-9863?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-9863?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20171003011446" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930215510/https://www.guideline.gov/summaries/downloadcontent/ngc-9863?contentType=xml" title="30 Sep 2016"><strong>Sep</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 01:14:46 Oct 03, 2017">OCT</td>
		  <td class="f" nowrap="nowrap">Nov</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930215510/https://www.guideline.gov/summaries/downloadcontent/ngc-9863?contentType=xml" title="21:55:10 Sep 30, 2016"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 01:14:46 Oct 03, 2017">03</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930215510/https://www.guideline.gov/summaries/downloadcontent/ngc-9863?contentType=xml" title="30 Sep 2016"><strong>2016</strong></a></td>
		  <td class="c" id="displayYearEl" title="You are here: 01:14:46 Oct 03, 2017">2017</td>
		  <td class="f" nowrap="nowrap">2018</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20171003011446*/https://www.guideline.gov/summaries/downloadcontent/ngc-9863?contentType=xml" title="See a list of every capture for this URL">2 captures</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016 - 03 Oct 2017</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-9863?contentType=xml","2017-10-03",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Risk reduction of prostate cancer with drugs or nutritional supplements.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Fleshner N, Ivers N, Lukka H, Shayegan B, Walker-Dilks C, Winquist E, Genitourinary Cancer Disease Site Group. Risk reduction of prostate cancer with drugs or nutritional supplements. Toronto (ON): Cancer Care Ontario (CCO); 2012 May 17. Various p.&amp;nbsp;(Evidence-based series; no. 3-3).&amp;nbsp; [75 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from reviewing and updating activities.</p>
<p>Please visit the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=139625&quot; title=&quot;Cancer Care Ontario Web site&quot;>Cancer Care Ontario Web site</a> for details on any new evidence that has emerged and implications to the guidelines.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Recommendation 1</strong></p>
<p>In men who are being assessed and monitored for prostate cancer, it is reasonable to offer 5-alpha-reducatase inhibitor (5-ARI) therapy if:</p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>They are &amp;ge;50 years of age with a normal prostate-specific antigen (PSA) level or </li>
    <li>They have an elevated PSA level (2.5 to 10 ng/mL) and a negative result on prostate biopsy or </li>
    <li>They have moderately symptomatic benign prostatic hyperplasia (BPH) </li>
</ol>
<p>in order to reduce the risk of needing definitive treatment for prostate cancer.</p>
<p>Men who meet these criteria should discuss the pros and cons of this option with their physician. 5-ARI therapy is not being recommended on a population-wide scale.</p>
<p><strong>Recommendation 2</strong></p>
<p>Vitamin E and selenium should not be used to reduce prostate cancer risk.</p></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Prostate cancer</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Assessment of Therapeutic Effectiveness"/>
      <fieldvalue value="Prevention"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Family Practice"/>
      <fieldvalue value="Internal Medicine"/>
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Preventive Medicine"/>
      <fieldvalue value="Urology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Patients"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To evaluate the effectiveness of drugs and nutritional supplements in reducing the risk of prostate cancer and prostate cancer-related death in patients without a diagnosis of prostate cancer</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Men older than or equal to 18 years of age who are being assessed and monitored for prostate cancer</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>5-alpha-reducatase inhibitor (5-ARI) therapy </li>
    <li>Vitamin E and selenium nutritional supplements (not recommended to reduce prostate cancer risk) </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Prostate cancer risk reduction </li>
    <li>Rate of prostate cancer </li>
    <li>Adverse effects of treatment </li>
    <li>Mortality </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Hand-searches of Published Literature (Primary Sources)"/>
      <fieldvalue value="Hand-searches of Published Literature (Secondary Sources)"/>
      <fieldvalue value="Searches of Electronic Databases"/>
      <fieldvalue value="Searches of Unpublished Data"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Literature Search Strategy</strong></p>
<p>A literature search was performed to identify published studies specifically addressing the prevention of prostate cancer. Searches were run in MEDLINE (1950 to 17 October 2011), EMBASE (1980 to 17 October 2011), and the Cochrane Library (April 2011). Relevant abstracts were searched in the conference proceedings of the American Society of Clinical Oncology (ASCO), the American Urological Association (AUA), and the European Association of Urology for the past three years. Relevant practice guidelines, technology assessments, and systematic reviews were searched in the U.S. National Guideline Clearinghouse, the U.K. National Institute for Health and Care Excellence, the Canadian Partnership Against Cancer - Cancer Guidelines Resource Centre, Canadian Medical Association (CMA) Infobase, and the U.K. National Institute for Health Research - Health Technology Assessment Programme. Reference lists of relevant articles were scanned, and experts in the field were consulted.</p>
<p><strong>Study Selection Criteria</strong></p>
<p>The literature searches were designed to retrieve English-language systematic reviews, meta-analyses, randomized controlled trials (RCTs), and clinical practice guidelines that evaluated drugs or nutritional supplements for the prevention of prostate cancer. RCTs had to include 50 or more patients. Systematic reviews and meta-analyses had to include a detailed description of the review methods (literature search, study selection, and data extraction) in the text of the article and one or more RCTs meeting the above criteria. Studies of healthy volunteers and patients at risk for prostate cancer (e.g., patients with high-grade prostatic intraepithelial neoplasia [HGPIN]) were eligible for inclusion.</p>
<p>Studies and reviews were excluded if the outcome was recurrence of prostate cancer. Studies were also excluded if the intervention focused on diet modification or healthy lifestyle (e.g., consumption of foods rich in certain vitamins or minerals, exercise, other non-drug interventions) rather than on taking specific drugs or supplements.</p>
<p>All studies identified by the literature search were assessed against the selection criteria by three reviewers. Discrepancies regarding eligibility were resolved by consensus.</p>
<p>Appendix 1 of the original guideline document contains a summary of the search strategies conducted in MEDLINE and EMBASE and Appendix 2 provides a flow chart of the search process.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A total of 35 articles met the inclusion criteria: one practice guideline, 13 systematic reviews, and 21 randomized controlled trials (RCTs) (16 full publications and five abstracts). See Appendix 2 in the original guideline document for a flow chart of the search process. The 13 systematic reviews encompassed 32 reports of 25 RCTs (see Appendix 3 in the original guideline document).</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Expert Consensus (Committee)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Meta-Analysis of Randomized Controlled Trials"/>
      <fieldvalue value="Review of Published Meta-Analyses"/>
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Quality Appraisal</strong></p>
<p>The methodological quality of the eligible studies was assessed by the same three reviewers. The A Measurement Tool to Assess Systematic Reviews (AMSTAR) tool was applied to evaluate the systematic reviews. The randomized controlled trials (RCTs) were examined with respect to indicators of methodological rigour, including random allocation, allocation concealment, blinding, handling of patient withdrawals and dropouts, and intention-to-treat analysis.</p>
<p>The Appraisal of Guidelines for Research and Evaluation II (AGREE II) Instrument was applied to any clinical practice guidelines that met the inclusion criteria. The AGREE Instrument evaluates the process of practice guideline development and the quality of reporting. The Standards and Guidelines Evidence (SAGE) Inventory of Cancer Guidelines (<a href=&quot;http://www.cancerguidelines.ca/Guidelines/inventory/index.php&quot; title=&quot;Standards and Guidelines Evidence (SAGE) Inventory of Cancer Guidelines Web site&quot;>http://www.cancerguidelines.ca/Guidelines/inventory/index.php</a>) was checked because AGREE II scores are included for all guidelines in the inventory. The Inventory of Cancer Guidelines is a searchable database of over 1,100 English language cancer control guidelines and standards released since 2003, developed and maintained by the Canadian Partnership Against Cancer's Capacity Enhancement Program.</p>
<p><strong>Synthesizing the Evidence</strong></p>
<p>When two or more trials provided appropriate data on outcomes of interest, statistical pooling using meta-analysis was done using Review Manager software (RevMan 5.1) provided by the Cochrane Collaboration. A random effects model was used for all pooling, because it provides a more conservative estimate. Pooled results are expressed as relative risks (RRs) with 95% confidence intervals (CIs). An RR of less than one favours the drug/supplement, and an RR of greater than one favours the placebo or control intervention.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Methods</strong></p>
<p>The Evidence-Based Series (EBS) guidelines developed by the Cancer Care Ontario Program in Evidence-Based Care (CCO PEBC) use the methods of the Practice Guidelines Development Cycle. For this project, the core methodology used to develop the evidentiary base was the systematic review. Evidence was selected and reviewed by two members of the PEBC Genitourinary Disease Site Group (GU DSG) and one methodologist.</p>
<p>The body of evidence in this review is primarily comprised of systematic reviews and mature randomized controlled trials (RCTs). That evidence forms the basis of the recommendations developed by the GU DSG. The systematic review and companion recommendations are intended to promote evidence-based practice in Ontario, Canada.</p>
<p><strong>Development and Internal Review</strong></p>
<p>The series is a convenient and up-to-date source of the best available evidence on reduction of prostate cancer, developed through review of the evidentiary base, evidence synthesis, and input from external review participants in Ontario. The GU DSG is comprised of medical and radiation oncologists, urologists, and pathologists with expertise in GU cancer, plus a lay representative and a methodologist. Review of the document by members of the DSG was generally positive. There were some requests for clearer wording in the first recommendation.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="External Peer Review"/>
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Report Approval Panel (RAP) Review and Approval</strong></p>
<p>Prior to the submission of this evidence-based series (EBS) draft report for external review, the report was reviewed and approved by the Program in Evidence-based Care (PEBC) RAP, a panel that includes oncologists and whose members have clinical and methodological expertise.</p>
<p><strong>External Review by Ontario Clinicians and Other Experts</strong></p>
<p>The PEBC external review process is two-pronged and includes a targeted peer review that is intended to obtain direct feedback on the draft report from a small number of specified content experts and a professional consultation that is intended to facilitate dissemination of the final guidance report to Ontario practitioners.</p>
<p>Following the review and discussion of Section 1: Recommendations and Section 2: Evidentiary Base of this EBS and the review and approval of the report by the PEBC RAP, the Genitourinary Disease Site Group (GU DSG) circulated Sections 1 and 2 to external review participants for review and feedback.</p>
<p><em>Methods</em></p>
<p><span style=&quot;text-decoration: underline;&quot;>Targeted Peer Review</span></p>
<p>During the guideline development process, nine targeted peer reviewers from Ontario and the United States who were considered to be clinical and/or methodological experts on the topic were identified by the GU DSG. Several weeks prior to completion of the draft report, the nominees were contacted by email and asked to serve as reviewers. Three reviewers agreed and the draft report and a questionnaire were sent via email for their review. The questionnaire consisted of items evaluating the methods, results, and interpretive summary used to inform the draft recommendations and whether the draft recommendations should be approved as a guideline. Written comments were invited. The questionnaire and draft document were sent out November 3, 2011. Follow-up reminders were sent at two weeks (email) and at four weeks (telephone call). The Working Group reviewed the results of the survey.</p>
<p><span style=&quot;text-decoration: underline;&quot;>Professional Consultation</span></p>
<p>Feedback was obtained through a brief online survey of health care professionals who are the intended users of the guideline. Urologists, oncologists specializing in genitourinary cancers, and primary care providers in the PEBC database were contacted by email to inform them of the survey. Participants were asked to rate the overall quality of the guideline (Section 1 in the original guideline document) and whether they would use and/or recommend it. Written comments were invited. Participants were contacted by email and directed to the survey website where they were provided with access to the survey, the guideline recommendations (Section 1 in the original guideline document) and the evidentiary base (Section 2 in the original guideline document). The notification email was sent on November 4, 2011. The consultation period ended on December 15, 2011. The Working Group reviewed the results of the survey.</p>
<p><strong>Conclusion</strong></p>
<p>This EBS report reflects the integration of feedback obtained through the external review process with final approval given by the GU DSG and the RAP of the PEBC.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The recommendations are supported by a clinical practice guideline, systematic reviews, and randomized controlled trials.</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Two randomized controlled trials (RCTs) (44,000 person years of exposure) showed a pooled relative risk reduction for local, biopsy-confirmed prostate cancer of 23% (95% confidence interval [CI], 18 to 27) and number needed to treat (NNT) of 18 (95% CI, 15 to 23).
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>One RCT comparing finasteride, 5 mg/d, with placebo (n=18,882), showed a relative risk reduction of 25% (95% CI, 19 to 31) in the period prevalence of prostate cancer over seven years, with an NNT of 17 (95% CI, 13 to 23). Removing those diagnosed by protocol-mandated biopsy from analysis resulted in a relative risk reduction of 10% (95% CI, 0.09 to 19) and an NNT of 34 (95% CI, 17 to 4,202). </li>
        <li>One RCT comparing dutasteride, 0.5 mg/d, with placebo (n=8,231), showed a relative risk reduction of 23% (95% CI, 15 to 30) in the incidence of prostate cancer over four years, with an NNT of 20 (95% CI, 15 to 32) (2). </li>
    </ul>
    </li>
    <li>Meta-analysis of six trials (n=12,857) comparing 5-alpha-reducatase inhibitors (5-ARIs) with placebo/non-5-ARIs in men with benign prostatic hyperplasia (BPH) showed a relative risk reduction of 29% (95% CI, 8 to 46) in the period prevalence of prostate cancer, with an NNT of 104 (95% CI, 66 to 375). </li>
</ul>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>5-Alpha-Rducatase Inhibitors (5-ARIs)</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>There may be a small increased risk of high-grade prostate cancer with 5-ARI therapy. The pooled number needed to harm for high-grade (Gleason score 8 to 10) prostate cancer for two randomized controlled trials (RCTs) was 134 (95% confidence interval [CI], 77 to 293). Alternatively, this could represent a detection bias related to a more effective detection of these cancers in men on 5-ARIs. Nevertheless, the magnitude of this risk, if real, is likely outweighed by the benefits of avoiding overtreatment for biologically insignificant prostate cancer, especially given that these men should be closely monitored. </li>
    <li>As the risk of sexual dysfunction increases with age as well as with 5-ARI therapy, sexual dysfunction rates may be perceived to be higher in clinical practice than when reported in the RCTs. Men should be explicitly asked about such side effects and the risk-benefit ratio of 5-ARI therapy reconsidered if sexual dysfunction is concerning to the patient. </li>
</ul>
<p>See the &quot;Adverse Effects&quot; sections of the original guideline document for more information.</p></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>It is important for the user to recognize that the recommendation simply urges that it is worth a conversation about the use of 5-alpha-reducatase inhibitor (5-ARI) therapy between a man (who meets the above criteria) and his physician. </li>
    <li>It is important to acknowledge that the recommendations received mixed reviews from clinicians who participated in the external review of this document (see Section 3 in the original guideline document). </li>
    <li>The user must consider their view of what constitutes &quot;worthwhile&quot; cancer risk reduction when reading this recommendation. Ideally, drugs effective for prostate cancer risk reduction would be offered only to individuals at high risk for fatal forms of the disease. Currently, such knowledge is lacking, and so different perspectives on the value and application of imperfect drugs such as 5-ARIs is expected. Three perspectives are of specific relevance. First, as none of the randomized controlled trials (RCTs) of 5-ARI therapy reported any reduction in overall or prostate cancer-specific mortality, 5-ARI therapy must be considered an unproven intervention from this perspective. Second, as two large RCTs of 5-ARI therapy both reported a small but real increase in higher grade prostate cancers, 5-ARI therapy could be considered ineffective from the perspective of the &quot;first do no harm&quot; principle. A third perspective argues that the observation of more high-grade cancers is due to detection artefacts not 5-ARI therapy. This guideline recommendation offers an alternative perspective that the value of drug therapy for prostate cancer risk reduction should consider the contemporary clinical context. 5-ARI therapy may be worthwhile to reduce prostate cancer risk in a clinical context where case finding is routine due to screening; aggressive anticancer treatment (with uncertain benefits and certain risks) is routinely pursued by and offered to patients; and uncertainties regarding the safety and efficacy of more conservative approaches such as surveillance remain. From this perspective, the recommendation considers the current risk of being &quot;overtreated&quot; for prostate cancer as easily exceeding the small risk associated with developing a high-grade (and still potentially curable) cancer due to 5-ARI therapy. </li>
    <li>The Genitourinary Disease Site Group (GU DSG) recognizes the challenge of weighing this complex set of benefits and risks for each patient. Formal decision aids would be useful to help patients and providers make shared, informed decisions on the use of 5-ARIs for the reduction of prostate cancer. A decision aid on the use of finasteride is available from the American Society for Clinical Oncology: providers and patients may benefit from using this until a revised version is developed that includes all the data synthesized in this review. </li>
    <li>5-ARI therapy has been shown to reduce the risk of less aggressive prostate cancer (pooled number needed to treat [NNT] for detection of one less prostate cancer during the period of the studies=18), but not to reduce prostate cancer mortality or overall mortality. Currently, many men with slower progressing prostate cancer are treated with surgery or radiotherapy even though such treatment may not be necessary. The GU DSG highly values reducing the number of men treated in this aggressive manner and, therefore, considers the above recommendation reasonable. If the ability and willingness to precisely identify and observe men with biologically indolent prostate cancers emerges in the future, these recommendations would need to be re-evaluated. </li>
    <li>5-ARI chemoprevention for men without benign prostatic hyperplasia (BPH) should only be considered for those who have initially decided to pursue regular monitoring for prostate cancer development, with the PSA test based on an informed choice regarding risks and benefits, and for those who are committed to ongoing monitoring. The NNT to prevent detection of one case of prostate cancer was higher in this group (NNT=94). Although the optimal monitoring schedule for men receiving 5-ARI therapy to reduce their risk of prostate cancer is uncertain, evidence from the Prostate Cancer Prevention Trial (PCPT) and Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trials suggests that they should visit their clinic every six to 12 months for PSA and digital rectal examination (DRE) testing and assessment of medical symptoms and side effects. A low threshold for prostate biopsy in the presence of rising PSA, abnormal DRE, or clinical concerns of the treating physician is appropriate. </li>
    <li>The optimal 5-ARI regimen and duration of therapy are uncertain. In the primary RCTs considered, finasteride 5.0 mg orally (po) daily was given for a planned seven years and dutasteride 0.5 mg po was given daily for four years. </li>
    <li>The expected NNT in clinical practice will likely be much higher, as the diagnosis of prostate cancer in men without BPH was usually made by protocol-mandated prostate biopsy and not for suspicion of prostate cancer. </li>
    <li>Potential recipients of 5-ARI therapy should be well informed about the potential risks. There may be a small increased risk of high-grade prostate cancer with 5-ARI therapy. The pooled number needed to harm for high-grade (Gleason score 8 to 10) prostate cancer for the two RCTs was 134 (95% confidence interval [CI], 77 to 293). Alternatively, this could represent a detection bias related to a more effective detection of these cancers in men on 5-ARIs. Nevertheless, the magnitude of this risk, if real, is likely outweighed by the benefits of avoiding overtreatment for biologically insignificant prostate cancer, especially given that these men should be closely monitored. </li>
    <li>As the risk of sexual dysfunction increases with age as well as with 5-ARI therapy, sexual dysfunction rates may be perceived to be higher in clinical practice than when reported in the RCTs. Men should be explicitly asked about such side effects and the risk-benefit ratio of 5-ARI therapy reconsidered if sexual dysfunction is concerning to the patient. </li>
    <li>5-ARI chemoprevention is inappropriate in men with limited life expectancy and/or substantial comorbid conditions for whom definitive treatment of prostate cancer would not be pursued. </li>
    <li>Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way. </li>
</ul>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Quick Reference Guides/Physician Guides"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Staying Healthy"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Patient-centeredness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Fleshner N, Ivers N, Lukka H, Shayegan B, Walker-Dilks C, Winquist E, Genitourinary Cancer Disease Site Group. Risk reduction of prostate cancer with drugs or nutritional supplements. Toronto (ON): Cancer Care Ontario (CCO); 2012 May 17. Various p.&amp;nbsp;(Evidence-based series; no. 3-3).&amp;nbsp; [75 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2012 May 17"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]"/>
    </field>
    <field fieldid="123" ordby="1230" id="448" name="Guideline Developer Comment" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.</p></div>"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Program in Evidence-based Care (PEBC) is a provincial initiative of Cancer Care Ontario supported by the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from its funding source.</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Genitourinary Cancer Disease Site Group</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>For a current list of past and present members, please see the <a href=&quot;https://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/genito-ebs/genito-dsg/&quot; title=&quot;Cancer Care Ontario Web site&quot;>Cancer Care Ontario Web site</a>.</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>In accordance with the Program in Evidence-based Care (PEBC) Conflict of Interest (COI) Policy, the guideline authors, Genitourinary Disease Site Group (GU DSG) members, and internal and external reviewers were asked to disclose potential conflicts of interest.</p>
<p>Neil Fleshner</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Grant/support as principal or co-investigator: Unrestricted educational grant from GSK </li>
    <li>Principal investigator for a clinical trial involving the topic: GSK supported clinical trials &amp;ndash; REDEEM and REDUCE </li>
    <li>Published on the topic: GU ASCO Meeting Feb 2011: Abstract Submission ID: 72231 Abstract Title: Effect of dutasteride on prostate cancer progression and cancer diagnosis on rebiopsy in the REDEEM active surveillance study; Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, Farley A, Jansz K, Siemens DR, Trpkov K, Lacombe L, Gleave M, Tu D, Parulekar WR. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-e, soy, and selenium. J Clin Oncol. 2011 Jun 10;29(17):2386-90. </li>
</ul>
<p>Jack Barkin</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Grant support: Researcher/investigator for CombAT, REDUCE and REDEEM trials sponsored by GSK </li>
</ul>
<p>All other Working Group members and GU DSG members declared no conflict of interest.</p>
<p><strong>Report Approval Panel</strong></p>
<p>All Report Approval Panel members declared no conflict of interest.</p>
<p><strong>External Reviewers</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>One external reviewer declared &amp;ge;$5000.00 in a single year to act in a consulting capacity for the US Prostate, Lung, Colon, and Ovary Screening Trial (Division of Cancer Prevention, National Cancer Institute, Bethesda, MD) and has published extensively on screening, including prostate cancer screening. </li>
    <li>One reviewer has published extensively on chemoprevention of prostate cancer. </li>
    <li>One external reviewer declared &amp;ge;$5000.00 in a single year to act in a consulting capacity for Sanofi International Strategy Board, received grants as a principal or co-investigator from Eli Lilly, and had managerial responsibility for an organization that has received &amp;ge;$5000.00 in a single year from a relevant business entity. </li>
</ul></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from reviewing and updating activities.</p>
<p>Please visit the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=139625&quot; title=&quot;Cancer Care Ontario Web site&quot;>Cancer Care Ontario Web site</a> for details on any new evidence that has emerged and implications to the guidelines.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=139625&quot; title=&quot;Cancer Care Ontario Web site&quot;>Cancer Care Ontario Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following are available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Risk reduction of prostate cancer with drugs or nutritional supplements. Summary. Toronto (ON): Cancer Care Ontario (CCO). 2012 May 17. 9 p. Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=139623&quot; title=&quot;Cancer Care Ontario (CCO) Web site&quot;>Cancer Care Ontario (CCO) Web site</a>. </li>
    <li>Program in evidence-based care handbook. Toronto (ON): Cancer Care Ontario (CCO); 2012. 14 p. Electronic copies: Available in PDF from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=50876&quot; title=&quot;Cancer Care Ontario (CCO) Web site&quot;>CCO Web site</a>. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on September 6, 2013.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please refer to the <a href=&quot;http://www.cancercare.on.ca/ontariocancernews/copyright.html&quot; title=&quot;Cancer Care Ontario (CCO) Web site&quot;>Copyright and Disclaimer Statements</a> posted at the Program in Evidence-based Care section of the Cancer Care Ontario Web site.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 01:14:46 Oct 03, 2017 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 01:07:42 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 43.14 (3)
  esindex: 0.01
  captures_list: 62.746
  CDXLines.iter: 15.611 (3)
  PetaboxLoader3.datanode: 48.852 (4)
  exclusion.robots: 0.285
  exclusion.robots.policy: 0.272
  RedisCDXSource: 0.697
  PetaboxLoader3.resolve: 292.826
  load_resource: 305.181
-->